🚀 VC round data is live in beta, check it out!
Biote Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biote and similar public comparables like DocGo, Maternus-Kliniken, Radius Residential, P3 Health Partners and more.
Biote Overview
About Biote
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
Founded
2012
HQ
Employees
217
Website
Sectors
Financials (LTM)
EV
$134M
Biote Financials
Biote reported last 12-month revenue of $192M and EBITDA of $50M.
In the same LTM period, Biote generated $137M in gross profit, $50M in EBITDA, and $23M in net income.
Revenue (LTM)
Biote P&L
In the most recent fiscal year, Biote reported revenue of $192M and EBITDA of $53M.
Biote expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $192M | XXX | $192M | XXX | XXX | XXX |
| Gross Profit | $137M | XXX | $137M | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $50M | XXX | $53M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 28% | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $23M | XXX | $27M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | — | — | $83M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Biote Stock Performance
Biote has current market cap of $48M, and enterprise value of $134M.
Market Cap Evolution
Biote's stock price is $1.51.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $134M | $48M | 2.4% | XXX | XXX | XXX | $0.84 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiote Valuation Multiples
Biote trades at 0.7x EV/Revenue multiple, and 2.7x EV/EBITDA.
EV / Revenue (LTM)
Biote Financial Valuation Multiples
As of April 11, 2026, Biote has market cap of $48M and EV of $134M.
Equity research analysts estimate Biote's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biote has a P/E ratio of 2.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $48M | XXX | $48M | XXX | XXX | XXX |
| EV (current) | $134M | XXX | $134M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 2.7x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBIT | 4.0x | XXX | 3.7x | XXX | XXX | XXX |
| EV/Gross Profit | 1.0x | XXX | 1.0x | XXX | XXX | XXX |
| P/E | 2.1x | XXX | 1.8x | XXX | XXX | XXX |
| EV/FCF | 5.3x | XXX | 4.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biote Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Biote Margins & Growth Rates
Biote's revenue in the last 12 month grew by 2%.
Biote's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.5M for the same period.
Biote's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biote's rule of X is 21% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Biote Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | (17%) | XXX | (25%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Biote Public Comps
See public comps and valuation multiples for other Long-Term Care comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| DocGo | XXX | XXX | XXX | XXX | XXX | XXX |
| Maternus-Kliniken | XXX | XXX | XXX | XXX | XXX | XXX |
| Radius Residential | XXX | XXX | XXX | XXX | XXX | XXX |
| P3 Health Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| Joint | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biote M&A Activity
Biote acquired XXX companies to date.
Last acquisition by Biote was on XXXXXXXX, XXXXX. Biote acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Biote
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBiote Investment Activity
Biote invested in XXX companies to date.
Biote made its latest investment on XXXXXXXX, XXXXX. Biote invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Biote
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biote
| When was Biote founded? | Biote was founded in 2012. |
| Where is Biote headquartered? | Biote is headquartered in United States. |
| How many employees does Biote have? | As of today, Biote has over 217 employees. |
| Is Biote publicly listed? | Yes, Biote is a public company listed on Nasdaq. |
| What is the stock symbol of Biote? | Biote trades under BTMD ticker. |
| When did Biote go public? | Biote went public in 2022. |
| Who are competitors of Biote? | Biote main competitors are DocGo, Maternus-Kliniken, Radius Residential, P3 Health Partners. |
| What is the current market cap of Biote? | Biote's current market cap is $48M. |
| What is the current revenue of Biote? | Biote's last 12 months revenue is $192M. |
| What is the current revenue growth of Biote? | Biote revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Biote? | Current revenue multiple of Biote is 0.7x. |
| Is Biote profitable? | Yes, Biote is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biote? | Biote's last 12 months EBITDA is $50M. |
| What is Biote's EBITDA margin? | Biote's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Biote? | Current EBITDA multiple of Biote is 2.7x. |
| What is the current FCF of Biote? | Biote's last 12 months FCF is $25M. |
| What is Biote's FCF margin? | Biote's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Biote? | Current FCF multiple of Biote is 5.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.